Shionogi
OTC:SGIOFPharmaOsaka, Japan, Japan · Est. 1878 · 12,000 employees
Shionogi is a Japanese pharmaceutical company focused on developing and commercializing innovative medicines in infectious diseases, oncology, and other therapeutic areas.
4
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
5
Indications↗
Distinct diseases across all programs
77
Clinical Trials↗
All sponsored trials (all statuses)
15
Orange Book Patents
Across 2 drugs with upcoming expirations
Pipeline
Pipeline Snapshot
By Phase
4 drugs in development
Phase 24
Phase 11
By Therapeutic Area
top 4
Cardiovascular
120%
Infectious Disease
120%
Rare Disease
120%
Neurology
120%
R&D Momentum
35/100
Pipeline Velocity
27/100
Trial Completion Rate
92/100
Pipeline Concentration
20/100
Pipeline Freshness
80/100
Strategic Signals
- ↗Early-stage heavy pipeline may seek late-stage partners
- ↗Active in Cardiovascular but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Last 14 days
Jul 14, 2026
Completed
A Phase 1, Multicenter, Nonrandomized, Open-label, Parallel-group Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of S-892216-PO in Participants With Varying Degrees of Renal Impairment and Matched Control Participants With Normal Renal Function
Jul 8, 2026
Recruiting
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety, Tolerability, and Efficacy of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus Who Are at High Risk of Progression to Severe Disease
Jul 1, 2026
Completed
Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)
Earlier
Jun 24, 2026TrialA Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Investigate the Safety, Pharmacodynamics, and Preliminary Efficacy of S-606001 as an Add-on to Enzyme Replacement Therapy in Patients With Late-onset Pompe Disease
May 29, 2026FDAXocova — XOCOVA
Aug 30, 2025TrialPhase 1 Study of BPN14770 in Participants With Hepatic Impairment and Healthy Controls
Aug 25, 2025TrialStudy of BPN14770 in Participants With Severe Renal Impairment and Healthy Controls
Jul 29, 2025TrialStudy of S-892216 Long-acting Injectable (LAI) in Healthy Adult Participants
4 more events
Jul 18, 2025TrialA Study to Assess the Effects of BPN14770 on Rosuvastatin
Jun 6, 2025TrialA Study of S-892216 in Participants With COVID-19
May 13, 2025TrialStudy of Zatolmilast (BPN14770) in Participants With PPP2R5D Neurodevelopmental Disorder (Jordan's Syndrome [JS])
Dec 30, 2024TrialA Drug-Drug Interaction Study of S-217622 With Combined Oral Contraceptives in Healthy Adult Female Participants
Details
Company Info
Company Overview
$20.0B
Mkt Cap
$2.8B
Revenue
—
Cash
CEOIsao Teshirogi
Founded1878
Employees12,000
HQOsaka, Japan, Japan
ExchangeOTC:SGIOF
Websiteshionogi.com
LinkedInCompany Page
Therapeutic Focus
Metabolic & EndocrineInfectious DiseaseGastroenterologyOncologyCardiovascularNeurologyOtherNephrologyRare DiseasePsychiatryImmunologyRespiratory
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Cardiovascular
Infectious Disease
Neurology
Rare Disease
Unknown / Other
Cardiovascular
Ischemic Stroke
RedasemtidePhase 2
Infectious Disease
Neurology
Cognitive Impairment
BPN14770Phase 1
Rare Disease
Pompe Disease
S-606001Phase 2
Unknown / Other
Fragile X Syndrome
BPN14770Phase 2
Regulatory
Regulatory Timeline
19931 event
FDASep 9
Cognex — COGNEX
Application NDA020070 (NDA)
20092 events
FDAApr 9
Ulesfia — ULESFIA
Application NDA022129 (NDA)
FDAApr 9
Ulesfia — ULESFIA
Application NDA022129 (NDA)
20101 event
FDAOct 5
Doribax — DORIBAX
Application NDA022106 (NDA)
20171 event
FDAMay 5
Radicava — RADICAVA
Application NDA209176 (NDA)
20191 event
FDANov 14
Fetroja — FETROJA
Application NDA209445 (NDA)
20221 event
FDAMay 12
Radicava — RADICAVA ORS
Application NDA215446 (NDA)
20261 event
FDAMay 29
Xocova — XOCOVA
Application NDA220442 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)